Nebius Stock: The $50 Billion Backlog Test

As Nebius shares hover near record highs, having surged approximately 94% year-to-date, the market’s focus is laser-locked on a single date: April 29. The AI infrastructure provider will release its Q1 2026 earnings, a report that must validate both its stratospheric valuation and its ability to execute on the most ambitious expansion plan in the sector.

The fundamental bull case is built on an enviable foundation. The company has secured contracts with Microsoft and Meta, creating a combined order backlog of nearly $50 billion for the period from 2027 to 2031. Strategic partner Nvidia has also invested $2 billion directly. This backlog fuels an aggressive capacity ramp. Nebius aims to grow its data center capacity from 170 megawatts at the end of 2025 to between 800 megawatts and 1 gigawatt by the close of 2026. To achieve this, the company plans capital expenditures of $16 to $20 billion this year alone, funding nine new sites across the U.S. and Europe.

Financing this breakneck growth is a central challenge. Nebius recently raised approximately $4.34 billion through a convertible note offering, with proceeds earmarked for new hardware and locations, such as a massive AI campus under construction in Missouri. The financial strain is evident; free cash flow was deeply negative in 2025 at -$3.66 billion. The company’s heavy reliance on just two mega-customers, Microsoft and Meta, remains a structural risk that analysts watch closely.

Wall Street’s sentiment is a study in contrasts, reflecting the stock’s dizzying rally. The majority of analysts maintain a bullish stance, with 27 buy recommendations and price targets ranging from $143 to $211. Bank of America raised its target to $175, citing new large orders and the construction of a data center in Finland. Goldman Sachs is even more optimistic, setting a $205 target following a major AI infrastructure deal. However, a note of caution is growing. Both Wolfe Research and Freedom Capital Markets have downgraded the stock to "Hold." Analysts question whether management can finance and implement its planned projects at the required speed, arguing the current valuation already prices in significant future success. Freedom Capital, while raising its target to $154, warned the rally has absorbed much of the near-term optimism.

Investors are also monitoring insider activity. In recent weeks, several executives sold shares under pre-arranged 10b5-1 trading plans. Chief Revenue Officer Marc Boroditsky sold 4,500 shares at an average price of $160.10 in mid-April. Director Elena Bunina disposed of approximately 20,000 shares between April 10 and 14 at prices ranging from $140 to $161. These planned sales are not seen as panic moves but add to the narrative of a fully valued stock.

All eyes now turn to the quarterly report. For 2026, management has guided for revenue between $3 billion and $3.4 billion, with an adjusted EBITDA margin around 40%. The pipeline for new contract signings is expected to exceed $4 billion this year. The ultimate annualized revenue target is set between $7 billion and $9 billion. The April 29 results must show that the capacity expansion is on track and that growth remains hyperbolic; the previous quarter saw revenue soar 547% year-over-year. With a forward price-to-sales multiple of nearly 12—far above the industry average of 3—and a 14-day RSI reading of 75 signaling overbought conditions, the stock has little room for error. Any disappointment on revenue or utilization could abruptly reset the valuation debate.

Ad

Nebius Stock: New Analysis - 20 April

Fresh Nebius information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Nebius analysis...

Ad

Nebius Stock: New Analysis - 20 April

Fresh Nebius information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Nebius analysis...